GYNODIOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GYNODIOL (GYNODIOL).
Estradiol acts by binding to nuclear estrogen receptors, which modulate gene transcription and lead to the development and maintenance of female reproductive tissues and secondary sexual characteristics. Norethindrone acetate is a progestin that suppresses gonadotropin secretion and induces secretory changes in the endometrium.
| Metabolism | Estradiol is primarily metabolized in the liver via CYP3A4, with some involvement of CYP1A2 and CYP2C9, to estrone and estriol. Norethindrone acetate is metabolized in the liver via CYP3A4 to inactive metabolites. |
| Excretion | Renal 50-80% as metabolites and conjugates; biliary/fecal 10-20%; unchanged drug <5%. |
| Half-life | Terminal half-life approximately 24-30 hours; steady-state reached by 5-7 days. |
| Protein binding | 97-99% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | 0.7-1.0 L/kg; distributes into body water and adipose tissue. |
| Bioavailability | Oral: 40-60% due to first-pass metabolism. |
| Onset of Action | Oral: 2-4 hours to peak serum levels; clinical effects (e.g., menstrual regulation) within first cycle. |
| Duration of Action | Clinical effects persist for duration of treatment; hormonal suppression lasts 24-48 hours after last dose. |
| Molecular Weight | 312.45 |
1 tablet (ethinylestradiol 0.035 mg/norethisterone 1 mg) orally once daily for 21 days, followed by 7 days of placebo or hormone-free interval.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment recommended for GFR >30 mL/min. Use contraindicated in severe renal impairment (GFR <30 mL/min) due to risk of fluid retention and hyperkalemia. |
| Liver impairment | Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh A: use with caution; no specific dose adjustment but monitor liver function. |
| Pediatric use | Not indicated for use before menarche. For post-menarche adolescents >12 years: same as adult dosing; 1 tablet daily for 21 days followed by 7-day break. |
| Geriatric use | Not indicated for postmenopausal women. No specific dose adjustment; use only if benefit outweighs cardiovascular and thromboembolic risks. |
| 1st trimester | Contraindicated due to risk of fetal harm; estrogen exposure may cause congenital abnormalities. |
| 2nd trimester | Contraindicated; associated with fetal toxemia, metabolic bone disease, and other adverse outcomes. |
| 3rd trimester | Contraindicated; may induce premature closure of epiphyses, pituitary suppression, and other fetal risks. |
Clinical note
Comprehensive clinical and safety monograph for GYNODIOL (GYNODIOL).
| Placental transfer | Crosses placenta; documented transfer in human studies. |
| Breastfeeding | Excreted in breast milk in small amounts; may reduce milk production and quality; use only if clearly needed. |
| Lactation Rating |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events and probable dementia in women >65 years. Do not use for prevention of cardiovascular disease.
| Serious Effects |
Known or suspected pregnancyHistory of thrombophlebitis or thromboembolic disordersUndiagnosed abnormal genital bleedingKnown or suspected breast cancerKnown or suspected estrogen-dependent neoplasiaActive liver disease or impaired liver function
| Precautions | Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), Malignancies (e.g., breast cancer, endometrial cancer), Dementia risk in women >65 years, Gallbladder disease, Hypertriglyceridemia, Fluid retention, Hepatic hemangiomas or liver disease, Hypocalcemia, Ocular abnormalities (e.g., retinal thrombosis) |
| Food/Dietary | No specific dietary restrictions. Grapefruit juice may increase ethinylestradiol levels via CYP3A4 inhibition, but standard dietary amounts are unlikely to be clinically significant. Avoid excessive alcohol consumption as it may impair liver function and affect hormone metabolism. |
Loading safety data…
| L3 (Moderately Safe; potential for adverse effects) |
| Teratogenic Risk | GYNODIOL (estradiol valerate) is contraindicated in pregnancy. First trimester: Increased risk of congenital anomalies including cardiovascular and limb defects. Second and third trimesters: Fetal exposure may cause genitourinary tract abnormalities, feminization of male fetuses, and potential long-term reproductive effects. Use only if clearly needed for maternal condition. |
| Fetal Monitoring | Monitor fetal growth by ultrasound, amniotic fluid index, and fetal heart rate. Assess maternal blood pressure, liver function, and signs of estrogenic effects. In pregnancy, discontinue immediately and evaluate for potential teratogenicity. |
| Fertility Effects | Estradiol valerate can interfere with ovulation and endometrial receptivity, potentially reducing fertility. Intentional use for contraception is not indicated. Reversible upon discontinuation. |
| Clinical Pearls | GYNODIOL is a 0.01 mg ethinylestradiol/2 mg estradiol valerate combined oral contraceptive with a shortened hormone-free interval; it is important to counsel patients on the correct pill-taking schedule to minimize breakthrough bleeding and maintain contraceptive efficacy. |
| Patient Advice | Take one tablet daily at approximately the same time, with some food if needed to reduce nausea. · Be aware that break-through bleeding or spotting may occur, especially in the first few months. · Do not smoke while taking this medication, as smoking increases the risk of serious cardiovascular side effects. · If you miss a pill, follow the instructions in the package leaflet or consult your healthcare provider. · Use additional non-hormonal contraception (e.g., condoms) if you miss pills or have vomiting/diarrhea. · Seek immediate medical attention for symptoms of thrombotic events such as severe leg pain, chest pain, or sudden shortness of breath. |